Endpoints in asthma drug trials--what do they mean?
There are many potential outcomes or endpoints to choose from to assess the effects of asthma treatments, and a wide range of such measures are used in different trials. This can make it difficult to compare treatment outcomes from different trials and to understand whether new treatments offer a genuine clinical benefit for patients. Here we review the common endpoints used in trials to assess the efficacy of asthma treatments.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D023381:Endpoint Determination; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D010366:Peak Expiratory Flow Rate / Q000502:physiology; D011788:Quality of Life; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents